<p>新泽西州普林斯顿，2026 年 2 月 13 日（全球新闻通讯社）——ANI 制药公司（ANI 或公司）（纳斯达克：ANIP）今天宣布，公司将于 2026 年 2 月 27 日星期五在市场开盘前发布 2025 年第四季度和全年财务业绩。</p>
<p>公司总裁兼首席执行官 Nikhil Lalwani，财务高级副总裁兼首席财务官 Stephen P. Carey，以及罕见疾病负责人 Chris Mutz 将召开电话会议讨论业绩，具体如下：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>日期</td>
<td>2026 年 2 月 27 日星期五</td>
</tr>
<tr>
<td>时间</td>
<td>上午 8:00（东部时间）</td>
</tr>
<tr>
<td>免费电话（美国）</td>
<td>800-274-8461</td>
</tr>
<tr>
<td>会议 ID</td>
<td>5230834</td>
</tr>
<tr>
<td>网络直播（实时和回放）</td>
<td>www.anipharmaceuticals.com，位于 “投资者” 部分</td>
</tr>
</tbody>
</table>
<p>实时和存档的网络直播将可以通过公司网站 www.anipharmaceuticals.com 的投资者部分的活动和演示中访问。网络直播的回放将在活动后可访问 12 个月。</p>
<p><strong>关于 ANI</strong></p>
<p>ANI 制药公司（纳斯达克：ANIP）是一家多元化的生物制药公司，致力于其 “服务患者，改善生活” 的使命，通过开发、制造和商业化创新和高质量的治疗药物。公司专注于通过其罕见疾病业务实现可持续增长，该业务在眼科、风湿病、肾脏病、神经病学和肺病领域营销新产品；其仿制药业务利用研发专业知识、运营卓越和美国本土制造；以及其品牌业务。欲了解更多信息，请访问 www.anipharmaceuticals.com。</p>
<p><strong>投资者关系：</strong></p>
<p>Courtney Mogerley，Argot Partners</p>
<p>电话：646-368-8014</p>
<p>电子邮件：ani@argotpartners.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ESTVOQ00zTkRJME9UVXhJekl3TVRreU5qQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ESTVOQ00zTkRJME9UVXhJekl3TVRreU5qQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGU2MjBjMGItNDNjZi00NDU4LWEzYzQtOGM0MmQ3MDMwM2JjLTEwMzA4MzMtMjAyNi0wMi0xMy1lbg==/tiny/ANI-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGU2MjBjMGItNDNjZi00NDU4LWEzYzQtOGM0MmQ3MDMwM2JjLTEwMzA4MzMtMjAyNi0wMi0xMy1lbg==/tiny/ANI-Pharmaceuticals-Inc-.png"/></p>

ANI制药

<p>ANI 制药公司将于 2026 年 2 月 27 日东部时间上午 8:00 发布 2025 年第四季度和全年财务业绩。首席执行官 Nikhil Lalwani 及其他高管将主持电话会议，讨论业绩情况。公司网站将提供直播和录播的网络广播。ANI 制药专注于在包括罕见疾病、仿制药和品牌产品等多个医疗领域开发创新疗法</p>

<p>PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open.</p>
<div class="lb-trans"><p>新泽西州普林斯顿，2026 年 2 月 13 日（全球新闻通讯社）——ANI 制药公司（ANI 或公司）（纳斯达克：ANIP）今天宣布，公司将于 2026 年 2 月 27 日星期五在市场开盘前发布 2025 年第四季度和全年财务业绩。</p>
</div><p>Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows:</p>
<div class="lb-trans"><p>公司总裁兼首席执行官 Nikhil Lalwani，财务高级副总裁兼首席财务官 Stephen P. Carey，以及罕见疾病负责人 Chris Mutz 将召开电话会议讨论业绩，具体如下：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>Friday, February 27, 2026</td>
</tr>
<tr>
<td>Time</td>
<td>8:00 a.m. ET</td>
</tr>
<tr>
<td>Toll free (U.S.)</td>
<td>800-274-8461</td>
</tr>
<tr>
<td>Conference ID</td>
<td>5230834</td>
</tr>
<tr>
<td>Webcast (live and replay)</td>
<td>www.anipharmaceuticals.com, under the “Investors” section</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>日期</td>
<td>2026 年 2 月 27 日星期五</td>
</tr>
<tr>
<td>时间</td>
<td>上午 8:00（东部时间）</td>
</tr>
<tr>
<td>免费电话（美国）</td>
<td>800-274-8461</td>
</tr>
<tr>
<td>会议 ID</td>
<td>5230834</td>
</tr>
<tr>
<td>网络直播（实时和回放）</td>
<td>www.anipharmaceuticals.com，位于 “投资者” 部分</td>
</tr>
</tbody>
</table>
</div><p>The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 12 months following the event.</p>
<div class="lb-trans"><p>实时和存档的网络直播将可以通过公司网站 www.anipharmaceuticals.com 的投资者部分的活动和演示中访问。网络直播的回放将在活动后可访问 12 个月。</p>
</div><p><strong>About ANI</strong></p>
<div class="lb-trans"><p><strong>关于 ANI</strong></p>
</div><p>ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives&#34; by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&amp;D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.</p>
<div class="lb-trans"><p>ANI 制药公司（纳斯达克：ANIP）是一家多元化的生物制药公司，致力于其 “服务患者，改善生活” 的使命，通过开发、制造和商业化创新和高质量的治疗药物。公司专注于通过其罕见疾病业务实现可持续增长，该业务在眼科、风湿病、肾脏病、神经病学和肺病领域营销新产品；其仿制药业务利用研发专业知识、运营卓越和美国本土制造；以及其品牌业务。欲了解更多信息，请访问 www.anipharmaceuticals.com。</p>
</div><p><strong>Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>投资者关系：</strong></p>
</div><p>Courtney Mogerley, Argot Partners</p>
<div class="lb-trans"><p>Courtney Mogerley，Argot Partners</p>
</div><p>T: 646-368-8014</p>
<div class="lb-trans"><p>电话：646-368-8014</p>
</div><p>E: ani@argotpartners.com</p>
<div class="lb-trans"><p>电子邮件：ani@argotpartners.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ESTVOQ00zTkRJME9UVXhJekl3TVRreU5qQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1NDI5NCM3NDI0OTUxIzIwMTkyNjA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGU2MjBjMGItNDNjZi00NDU4LWEzYzQtOGM0MmQ3MDMwM2JjLTEwMzA4MzMtMjAyNi0wMi0xMy1lbg==/tiny/ANI-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZGU2MjBjMGItNDNjZi00NDU4LWEzYzQtOGM0MmQ3MDMwM2JjLTEwMzA4MzMtMjAyNi0wMi0xMy1lbg==/tiny/ANI-Pharmaceuticals-Inc-.png"/></p>

ANI 制药公司将在2026年2月27日上午 8 点（美国东部时间）讨论 2025 年第四季度及全年财务业绩 | ANIP 股票新闻